BACKGROUND:Interleukin-1 (IL-1) blockade seems to improve anaerobic exercise in patients with systolic heart failure through improved left ventricular (LV) systolic performance. However, it is unclear whether IL-1 blockade affects LV systolic performance. METHODS: We pooled data from 2 clinical trials of patients with systolic heart failure who were randomized to IL-1 blockade or placebo. We estimated changes in LV systolic performance (LV ejection fraction [LVEF] and end-systolic elastance [LVEes]) and pressure-volume area (PVA), a surrogate of oxygen consumption, after 14 days of treatment. RESULTS:LVEF increased from 30% (24%-38%) to 36% (29%-43%) between baseline and day 14 only in anakinra-treated patients (P = 0.03 for within-group change and P = 0.02 for between-group change compared with placebo). LVEes increased from 1.0 mm Hg/mL (0.7-1.5) to 1.3 mm Hg/mL (0.8-1.6) in anakinra-treated patients between baseline and day 14 but not in placebo-treated patients (P = 0.03 for within-group change and P = 0.08 for between-group change). A change in PVA between baseline and 14 days was not detected in either anakinra or placebo patients. CONCLUSIONS: In this post hoc analysis, LVEes and LVEF increased significantly in patients treated with an IL-1 blocker but not in placebo-treated patients. An effect of IL-1 blockade on calculated PVA was not detected.
RCT Entities:
BACKGROUND:Interleukin-1 (IL-1) blockade seems to improve anaerobic exercise in patients with systolic heart failure through improved left ventricular (LV) systolic performance. However, it is unclear whether IL-1 blockade affects LV systolic performance. METHODS: We pooled data from 2 clinical trials of patients with systolic heart failure who were randomized to IL-1 blockade or placebo. We estimated changes in LV systolic performance (LV ejection fraction [LVEF] and end-systolic elastance [LVEes]) and pressure-volume area (PVA), a surrogate of oxygen consumption, after 14 days of treatment. RESULTS: LVEF increased from 30% (24%-38%) to 36% (29%-43%) between baseline and day 14 only in anakinra-treated patients (P = 0.03 for within-group change and P = 0.02 for between-group change compared with placebo). LVEes increased from 1.0 mm Hg/mL (0.7-1.5) to 1.3 mm Hg/mL (0.8-1.6) in anakinra-treated patients between baseline and day 14 but not in placebo-treated patients (P = 0.03 for within-group change and P = 0.08 for between-group change). A change in PVA between baseline and 14 days was not detected in either anakinra or placebo patients. CONCLUSIONS: In this post hoc analysis, LVEes and LVEF increased significantly in patients treated with an IL-1 blocker but not in placebo-treated patients. An effect of IL-1 blockade on calculated PVA was not detected.
Authors: John S Gottdiener; James Bednarz; Richard Devereux; Julius Gardin; Allan Klein; Warren J Manning; Annitta Morehead; Dalane Kitzman; Jae Oh; Miguel Quinones; Nelson B Schiller; James H Stein; Neil J Weissman Journal: J Am Soc Echocardiogr Date: 2004-10 Impact factor: 5.251
Authors: Benjamin W Van Tassell; Nayef A Abouzaki; Claudia Oddi Erdle; Salvatore Carbone; Cory R Trankle; Ryan D Melchior; Jeremy S Turlington; Clinton J Thurber; Sanah Christopher; Dave L Dixon; Daniel T Fronk; Christopher S Thomas; Scott W Rose; Leo F Buckley; Charles A Dinarello; Giuseppe Biondi-Zoccai; Antonio Abbate Journal: J Cardiovasc Pharmacol Date: 2016-06 Impact factor: 3.105
Authors: Benjamin W Van Tassell; Ross A Arena; Stefano Toldo; Eleonora Mezzaroma; Tania Azam; Ignacio M Seropian; Keyur Shah; Justin Canada; Norbert F Voelkel; Charles A Dinarello; Antonio Abbate Journal: PLoS One Date: 2012-03-16 Impact factor: 3.240
Authors: Gustavo Monnerat; Micaela L Alarcón; Luiz R Vasconcellos; Camila Hochman-Mendez; Guilherme Brasil; Rosana A Bassani; Oscar Casis; Daniela Malan; Leonardo H Travassos; Marisa Sepúlveda; Juan Ignacio Burgos; Martin Vila-Petroff; Fabiano F Dutra; Marcelo T Bozza; Claudia N Paiva; Adriana Bastos Carvalho; Adriana Bonomo; Bernd K Fleischmann; Antonio Carlos Campos de Carvalho; Emiliano Medei Journal: Nat Commun Date: 2016-11-24 Impact factor: 14.919
Authors: Antonio Abbate; George F Wohlford; Marco Giuseppe Del Buono; Juan Guido Chiabrando; Roshanak Markley; Jeremy Turlington; Dinesh Kadariya; Cory R Trankle; Giuseppe Biondi-Zoccai; Michael J Lipinski; Benjamin W Van Tassell Journal: Eur Heart J Cardiovasc Pharmacother Date: 2022-08-11
Authors: Benjamin W Van Tassell; Cory R Trankle; Justin M Canada; Salvatore Carbone; Leo Buckley; Dinesh Kadariya; Marco G Del Buono; Hayley Billingsley; George Wohlford; Michele Viscusi; Claudia Oddi-Erdle; Nayef A Abouzaki; Dave Dixon; Giuseppe Biondi-Zoccai; Ross Arena; Antonio Abbate Journal: Circ Heart Fail Date: 2018-08 Impact factor: 8.790
Authors: Lisa K Mullany; Aarti D Rohira; John P Leach; Jong H Kim; Tanner O Monroe; Andrea R Ortiz; Brittany Stork; M Waleed Gaber; Poonam Sarkar; Andrew G Sikora; Todd K Rosengart; Brian York; Yongcheng Song; Clifford C Dacso; David M Lonard; James F Martin; Bert W O'Malley Journal: Proc Natl Acad Sci U S A Date: 2020-11-23 Impact factor: 11.205
Authors: Antonio Abbate; Cory R Trankle; Leo F Buckley; Michael J Lipinski; Darryn Appleton; Dinesh Kadariya; Justin M Canada; Salvatore Carbone; Charlotte S Roberts; Nayef Abouzaki; Ryan Melchior; Sanah Christopher; Jeremy Turlington; George Mueller; James Garnett; Christopher Thomas; Roshanak Markley; George F Wohlford; Laura Puckett; Horacio Medina de Chazal; Juan G Chiabrando; Edoardo Bressi; Marco Giuseppe Del Buono; Aaron Schatz; Chau Vo; Dave L Dixon; Giuseppe G Biondi-Zoccai; Michael C Kontos; Benjamin W Van Tassell Journal: J Am Heart Assoc Date: 2020-03-03 Impact factor: 6.106
Authors: George F Wohlford; Benjamin W Van Tassell; Hayley E Billingsley; Dinesh Kadariya; Justin M Canada; Salvatore Carbone; Virginia L Mihalick; Aldo Bonaventura; Alessandra Vecchié; Juan Guido Chiabrando; Edoardo Bressi; Georgia Thomas; Ai-Chen Ho; Amr A Marawan; Megan Dell; Cory R Trankle; Jeremy Turlington; Roshanak Markley; Antonio Abbate Journal: J Cardiovasc Pharmacol Date: 2020-10-24 Impact factor: 3.271